NLRP3 and liver disorder: Mcc950 specifically inhibits NLRP3 inflammasome activation in preclinical liver diseases, including steatohepatitis but a phase II clinical trial of Mcc950 for rheumatoid arthritis was suspended owing to hepatic toxicity [69,100].